Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus HP and nab-paclitaxel in HER2+ breast cancer
NCT04398914Phase 2Active, not recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started May 2020; status: active, not recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04398914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398914.